Aragen has an experienced team of in vivo pharmacologists with strong domain knowledge in various animal models of disease to obtain in vivo proof-of-concept across multiple therapeutic areas. We have over 60 validated models in Oncology, Inflammation, Autoimmune Disease, Pain, Fibrosis, Cardiovascular and Metabolic Diseases. Our screening modalities include small molecules, large molecules and antibodies. We follow acute, chronic, mechanistic and pharmacodynamic models to assess target engagement, efficacy, PK/PD correlation and biomarker evaluation, in collaboration with our in vitro pharmacology and DMPK teams. Our state-of-the-art vivarium and agile operational model enable quick allocation of appropriate space with technical staff to accelerate research programs. We provide specialized platforms and technical expertise, including ex vivo/in vitro testing, clinical pathology and histopathology and histological preparations. In addition to disease models in a multitude of therapeutic areas, we also undertake non-GLP pharmacokinetic (PK), pharmacodynamic (PD), and toxicology screens.
